Thyrocare Technologies Limited (THYROCARE) — Announcement | 13 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
🔄 What Changed
Promoter shareholding fell from 60.92% to 51.02%

Thyrocare announced that promoter Docon Technologies sold 1,57,69,696 shares, reducing its stake from 60.92% to 51.02% of the company's equity. This dilution lowers promoter control but maintains promoter status, potentially affecting governance perception and investor confidence in long-term stability.

📄 View Original Announcement (PDF)

About Thyrocare Technologies Limited (THYROCARE)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹9,566.63 Cr P/E: 35.2 ROE: 34.3% ROCE: 45.6% Div Yield: 1.16%

View full THYROCARE stock details →

📡 Get AI alerts when THYROCARE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track THYROCARE — Free

📊 More THYROCARE filings

See all THYROCARE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when THYROCARE files new disclosures

Track THYROCARE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track THYROCARE — Free

Free account · 2 AI queries/day